This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.
In the Largest Study of its Kind, Findings Highlight the Need to Increase Hepatitis C Testing and Treatment to Decrease Rates of Transmission, Morbidity, and Mortality
A new Quest Diagnostics Health Trends® report developed in collaboration with the Centers for Disease Control and Prevention (CDC) found that the COVID-19 pandemic reduced routine hepatitis C...
Combines Ginkgo's robust Concentric by Ginkgo pooled testing program with Quest's PCR/NAAT COVID-19 pooled specimen testing to support return to classrooms
Ginkgo Bioworks ("Ginkgo") today announced a collaboration with Quest Diagnostics (NYSE:DGX) to provide COVID-19 Kindergarten through Senior (K-12) school testing services to support classroom...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the BofA Securities 2021 Virtual Healthcare...
-- First quarter revenues of $2.72 billion, up 49.3% from 2020
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the first quarter ended March 31, 2021. "Quest...
GENEVA--(BUSINESS WIRE)--The Commons Project Foundation and the World Economic Forum today announced the global expansion of the CommonTrust Network (www.commontrustnetwork.org) to cover 32...
10 studies highlight Quest Diagnostics' commitment to specialty genetics testing and research in areas such as mitochondrial mtDNA analysis and next generation sequencing
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, and Blueprint Genetics announced today that they will present results of 10 studies at the virtual...
Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2021 financial results on Thursday, April...
Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced the sale of its minority share in Q2 Solutions to IQVIA (NYSE: IQV), a leading...
Zora Biosciences Oy, a clinical diagnostics company whose mission is to identify robust markers of disease and develop them into high-throughput, health-economic value-added clinical methods,...
- Company to repurchase $900 million of its shares in first half of 2021
At a virtual meeting with analysts and investors at its Investor Day, members of the senior management team of Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of...
